BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 36072806)

  • 1. Functionally Relevant Cytokine/Receptor Axes in Myelofibrosis.
    Pozzi G; Carubbi C; Cerreto GM; Scacchi C; Cortellazzi S; Vitale M; Masselli E
    Biomedicines; 2023 Sep; 11(9):. PubMed ID: 37760903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracking fibrosis in myeloproliferative neoplasms by CCR2 expression on CD34
    Pozzi G; Carubbi C; Gobbi G; Tagliaferri S; Mirandola P; Vitale M; Masselli E
    Front Oncol; 2022; 12():980379. PubMed ID: 36072806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The differences of hemogram, myelogram, and driver gene mutations in classic myeloproliferative neoplasms.
    Wang J; Zhang J; Huang J; Mei Y; Hong Z
    Blood Cells Mol Dis; 2022 Nov; 97():102698. PubMed ID: 35914897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.
    Keski H
    Blood Cells Mol Dis; 2020 May; 82():102420. PubMed ID: 32179412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis.
    Varricchio L; Hoffman R
    Front Oncol; 2022; 12():906698. PubMed ID: 35646681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Megakaryocyte Subpopulation Poised to Exert the Function of HSC Niche as Possible Driver of Myelofibrosis.
    Migliaccio AR
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Genetic Makeup of Myeloproliferative Neoplasms: Role of Germline Variants in Defining Disease Risk, Phenotypic Diversity and Outcome.
    Masselli E; Pozzi G; Carubbi C; Vitale M
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.
    Varricchio L; Iancu-Rubin C; Upadhyaya B; Zingariello M; Martelli F; Verachi P; Clementelli C; Denis JF; Rahman AH; Tremblay G; Mascarenhas J; Mesa RA; O'Connor-McCourt M; Migliaccio AR; Hoffman R
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34383713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the rs1024611 Polymorphism of
    Masselli E; Carubbi C; Pozzi G; Percesepe A; Campanelli R; Villani L; Gobbi G; Bonomini S; Roti G; Rosti V; Massa M; Barosi G; Vitale M
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.